| Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance JQ Wang, Y Yang, CY Cai, QX Teng, Q Cui, J Lin, YG Assaraf, ZS Chen Drug Resistance Updates 54, 100743, 2021 | 180 | 2021 |
| Chloroquine against malaria, cancers and viral diseases W Zhou, H Wang, Y Yang, ZS Chen, C Zou, J Zhang Drug Discovery Today 25 (11), 2012-2022, 2020 | 128 | 2020 |
| ATP‐binding cassette (ABC) transporters in cancer: A review of recent updates JQ Wang, ZX Wu, Y Yang, QX Teng, YD Li, ZN Lei, KA Jani, N Kaushal, ... Journal of Evidence‐Based Medicine 14 (3), 232-256, 2021 | 112 | 2021 |
| Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1-and ABCG2-overexpressing cancer cells N Ji, Y Yang, CY Cai, ZN Lei, JQ Wang, P Gupta, S Shukla, SV Ambudkar, ... Cancer letters 440, 82-93, 2019 | 107 | 2019 |
| Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression Z Pan, K Wang, X Wang, Z Jia, Y Yang, Y Duan, L Huang, ZX Wu, J Zhang, ... Molecular Cancer 21 (1), 1-17, 2022 | 81 | 2022 |
| Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells ZX Wu, QX Teng, CY Cai, JQ Wang, ZN Lei, Y Yang, YF Fan, JY Zhang, ... Biochemical pharmacology 166, 120-127, 2019 | 63 | 2019 |
| VS-4718 antagonizes multidrug resistance in ABCB1-and ABCG2-overexpressing cancer cells by inhibiting the efflux function of ABC transporters N Ji, Y Yang, CY Cai, ZN Lei, JQ Wang, P Gupta, QX Teng, ZS Chen, ... Frontiers in Pharmacology, 1236, 2018 | 58 | 2018 |
| Ulixertinib (BVD-523) antagonizes ABCB1-and ABCG2-mediated chemotherapeutic drug resistance N Ji, Y Yang, ZN Lei, CY Cai, JQ Wang, P Gupta, X Xian, DH Yang, ... Biochemical Pharmacology 158, 274-285, 2018 | 52 | 2018 |
| Reprogramming carcinoma associated fibroblasts by AC1MMYR2 impedes tumor metastasis and improves chemotherapy efficacy Y Ren, X Zhou, X Liu, H Jia, X Zhao, Q Wang, L Han, X Song, Z Zhu, ... Cancer Letters 374 (1), 96-106, 2016 | 49 | 2016 |
| Tivantinib, A c-met inhibitor in clinical trials, is susceptible to ABCG2-mediated drug resistance ZX Wu, Y Yang, QX Teng, JQ Wang, ZN Lei, JQ Wang, S Lusvarghi, ... Cancers 12 (1), 186, 2020 | 45 | 2020 |
| Erdafitinib antagonizes ABCB1-mediated multidrug resistance in cancer cells W Feng, M Zhang, ZX Wu, JQ Wang, XD Dong, Y Yang, QX Teng, ... Frontiers in Oncology 10, 955, 2020 | 44 | 2020 |
| Overexpression of ABCB1 transporter confers resistance to mTOR inhibitor WYE-354 in cancer cells J Wang, DH Yang, Y Yang, JQ Wang, CY Cai, ZN Lei, QX Teng, ZX Wu, ... International journal of molecular sciences 21 (4), 1387, 2020 | 41 | 2020 |
| Gaseous signaling molecules and their application in resistant cancer treatment: from invisible to visible Q Cui, Y Yang, N Ji, JQ Wang, L Ren, DH Yang, ZS Chen Future Medicinal Chemistry 11 (4), 323-336, 2019 | 37 | 2019 |
| Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3× anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells D Fan, W Li, Y Yang, X Zhang, Q Zhang, Y Yan, M Yang, J Wang, D Xiong Journal of hematology & oncology 8 (1), 1-12, 2015 | 37 | 2015 |
| Sitravatinib, a tyrosine kinase inhibitor, inhibits the transport function of ABCG2 and restores sensitivity to chemotherapy-resistant cancer cells in vitro Y Yang, N Ji, QX Teng, CY Cai, JQ Wang, ZX Wu, ZN Lei, S Lusvarghi, ... Frontiers in oncology 10, 700, 2020 | 35 | 2020 |
| Midostaurin reverses ABCB1-mediated multidrug resistance, an in vitro study N Ji, Y Yang, CY Cai, JQ Wang, ZN Lei, ZX Wu, Q Cui, DH Yang, ZS Chen, ... Frontiers in Oncology 9, 514, 2019 | 33 | 2019 |
| Overexpression of ABCC1 confers drug resistance to betulin XY Chen, Y Yang, JQ Wang, ZX Wu, J Li, ZS Chen Frontiers in oncology, 162, 2021 | 32 | 2021 |
| Dual TTK/CLK2 inhibitor, CC‐671, selectively antagonizes ABCG2‐mediated multidrug resistance in lung cancer cells ZX Wu, Y Yang, G Wang, JQ Wang, QX Teng, L Sun, ZN Lei, L Lin, ... Cancer Science 111 (8), 2872-2882, 2020 | 32 | 2020 |
| Glesatinib, a c-MET/SMO dual inhibitor, antagonizes P-glycoprotein mediated multidrug resistance in cancer cells Q Cui, CY Cai, HL Gao, L Ren, N Ji, P Gupta, Y Yang, S Shukla, ... Frontiers in Oncology 9, 313, 2019 | 31 | 2019 |
| Modulating the function of ABCB1: in vitro and in vivo characterization of sitravatinib, a tyrosine kinase inhibitor Y Yang, N Ji, CY Cai, JQ Wang, ZN Lei, QX Teng, ZX Wu, Q Cui, Y Pan, ... Cancer Communications 40 (7), 285-300, 2020 | 30 | 2020 |
